Delayed
Hong Kong S.E.
23:48:13 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
6.4
HKD
|
-1.84%
|
|
-9.22%
|
-47.71%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11,810
|
6,482
|
3,596
|
-
|
-
|
Enterprise Value (EV)
1 |
10,982
|
6,482
|
3,596
|
3,596
|
3,596
|
P/E ratio
|
-507
x
|
44.5
x
|
15.4
x
|
11.6
x
|
8.57
x
|
Yield
|
-
|
-
|
0.97%
|
1.05%
|
-
|
Capitalization / Revenue
|
21.6
x
|
9.74
x
|
4.14
x
|
3.17
x
|
2.43
x
|
EV / Revenue
|
21.6
x
|
9.74
x
|
4.14
x
|
3.17
x
|
2.43
x
|
EV / EBITDA
|
65.8
x
|
27.5
x
|
12.6
x
|
9.91
x
|
-
|
EV / FCF
|
61.7
x
|
46
x
|
15.4
x
|
12.5
x
|
10.5
x
|
FCF Yield
|
1.62%
|
2.17%
|
6.51%
|
7.98%
|
9.51%
|
Price to Book
|
-
|
3.96
x
|
2.01
x
|
1.78
x
|
-
|
Nbr of stocks (in thousands)
|
582,658
|
582,658
|
582,658
|
-
|
-
|
Reference price
2 |
20.27
|
11.13
|
6.171
|
6.171
|
6.171
|
Announcement Date
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
547.4
|
665.6
|
868.5
|
1,135
|
1,480
|
EBITDA
1 |
-
|
179.5
|
235.9
|
286
|
363
|
-
|
EBIT
1 |
-
|
121.7
|
219.8
|
269
|
346
|
438.5
|
Operating Margin
|
-
|
22.24%
|
33.02%
|
30.97%
|
30.48%
|
29.64%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
162.1
|
260.5
|
348
|
468
|
Net income
1 |
24.17
|
-21.76
|
145.5
|
232.5
|
309
|
418
|
Net margin
|
-
|
-3.98%
|
21.87%
|
26.77%
|
27.22%
|
28.25%
|
EPS
2 |
0.0500
|
-0.0400
|
0.2500
|
0.4000
|
0.5300
|
0.7200
|
Free Cash Flow
1 |
-
|
191.5
|
140.9
|
234
|
287
|
342
|
FCF margin
|
-
|
34.99%
|
21.17%
|
26.94%
|
25.29%
|
23.12%
|
FCF Conversion (EBITDA)
|
-
|
106.67%
|
59.75%
|
81.82%
|
79.06%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
96.83%
|
100.65%
|
92.88%
|
81.82%
|
Dividend per Share
2 |
-
|
-
|
-
|
0.0600
|
0.0650
|
-
|
Announcement Date
|
6/28/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
828
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
192
|
141
|
234
|
287
|
342
|
ROE (net income / shareholders' equity)
|
-
|
-3.35%
|
9.37%
|
13.5%
|
15.8%
|
17.7%
|
ROA (Net income/ Total Assets)
|
-
|
-1.38%
|
7.71%
|
11.1%
|
12.9%
|
14.3%
|
Assets
1 |
-
|
1,579
|
1,889
|
2,104
|
2,395
|
2,923
|
Book Value Per Share
2 |
-
|
-
|
2.810
|
3.070
|
3.470
|
-
|
Cash Flow per Share
2 |
-
|
-
|
0.2600
|
0.4500
|
0.5600
|
-
|
Capex
1 |
-
|
32.3
|
42.2
|
34
|
35
|
36
|
Capex / Sales
|
-
|
5.9%
|
6.34%
|
3.91%
|
3.08%
|
2.43%
|
Announcement Date
|
6/28/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
6.171
CNY Average target price
12.94
CNY Spread / Average Target +109.62% Consensus |
1st Jan change
|
Capi.
|
---|
| -47.71% | 495M | | +13.72% | 130B | | -17.54% | 7.17B | | +47.67% | 5.91B | | -33.48% | 4.02B | | +8.31% | 3.44B | | -19.83% | 2.46B | | -16.33% | 1.96B | | -24.61% | 1.67B | | -36.56% | 1.47B |
Medical Devices & Implants
|